Expression profiling of CD8+ T-cells in peripheral blood (PB) of AML patients

1) Transcriptional profiles of highly purified (≥ 98%) PB CD8+ T-cells from newly diagnosed AML patients (pre-treatment) were compared to age-matched healthy controls and transcriptional profiles of PB AML CD8+ T-cells from patients who achieved complete remission (CR) versus non-responders (NR) longitudinally, at pre-treatment and upon recovery following induction chemotherapy (paired samples). 2) Transcriptional profiles of PB AML CD8+ T-cells from patients who achieved complete remission (CR) versus non-responders (NR) longitudinally, at pre-treatment (PRE) and upon recovery following induction chemotherapy (POST) (paired samples). 1) AML patients vs. Healthy controls 2) AML patients induction chemotherapy responders (CR) versus non-responders (NR) at pretreatment (PRE) and upon recovery following induction chemotherapy (POST).